Is BioMark Diagnostics Inc. (BMKDF) a Buy, Sell, or Hold?
OTC : BMKDF
BioMark Diagnostics Inc.
$0.4003 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 2.2K
- Market Capitalization
- $42.07M
- P/E Ratio
- -38.30
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.50
- Year Low
- $0.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.99
Company Overview
OTC
Rashid Ahmed Maula Bux
Medical - Diagnostics & Research
Healthcare
BMKDF
9
CA
USD
Liquidity Metrics
2.19
0.99
0.99
0.56
0.00
Sales & Valuation
$59787
949.18
171.41
-51.92
-0.01
Profitability
-$0.0141
-$1.48M
-2470.76%
-2681.89%
-194.77%
-79.40%
P/E Metrics
-38.30
-0.83
-0.83
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
7.20
1/9
-$13914.0
$1.86M
$1.53M
-$1.61M
Key Metrics (TTM)
$57.91M
968.53
-40.46
0.99
-194.77%
-159.60%
-2.56%
-1.89%
177 days
Company Executives
| Name | Title |
|---|---|
| Jeff Haince | GM & Chief Scientific Officer |
| Brian Kai-Ming Cheng | Chief Technical Officer & Independent Director |
| Rashid Ahmed Maula Bux | Founder, Chief Executive Officer, President & Director |
| Guoyu Huang | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About BioMark Diagnostics Inc. (OTC:BMKDF) Stock
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc. ...
2026-07-31 08:30:00
Anchored in the 2026 global campaign's core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe World Lung Cancer Day, BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company") proudly aligns with leading international healthcare organizations demanding equal access to early detection by developing simple, accessible blood testing that empowers patients and physicians with critical diagnostic insights when it matters most.
2026-06-23 08:30:00
BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation.
2026-06-09 08:30:00
New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies. Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Patent Allowance for Application No.
Frequently Asked Questions
-
What is the current BioMark Diagnostics Inc. (BMKDF) stock price?
-
BioMark Diagnostics Inc.(OTC:BMKDF) stock price is $0.4003 in the last trading session. During the trading session, BMKDF stock reached the peak price of $0.5044 while $0.212 was the lowest point it dropped to. The percentage change in BMKDF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BMKDF stock was $0.
-
BMKDF's industry and sector of operation?
-
The OTC listed BMKDF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of BMKDF?
-
Jeff Haince | GM & Chief Scientific Officer
Brian Kai-Ming Cheng | Chief Technical Officer & Independent Director
Rashid Ahmed Maula Bux | Founder, Chief Executive Officer, President & Director
Guoyu Huang | Chief Financial Officer
| -
How many employees does BMKDF have?
-
Number of BMKDF employees currently stands at 9. BMKDF operates from 3851 Shell Road, Richmond, BC V6X 2W2, CA.
-
Link for BMKDF official website?
-
Official Website of BMKDF is: https://www.biomarkdiagnostics.com
-
How do I contact BMKDF?
-
BMKDF could be contacted at phone #604 370 0779 and can also be accessed through its website. BMKDF operates from 3851 Shell Road, Richmond, BC V6X 2W2, CA.
-
How many shares of BMKDF are traded daily?
-
The average number of BMKDF shares traded daily for last 3 months was 2.2K.
-
What is the market cap of BMKDF currently?
-
The market value of BMKDF currently stands at $42.07M with its latest stock price at $0.4003